Gemcitabine, Navelbine, and Doxorubicin as Treatment for Patients with Refractory or Relapsed T-Cell Lymphoma
Table 1
Clinical characteristics and prognostic factors for overall survival (OS) of all patients.
Characteristics
Number of patients (%)
Univariate
Multivariate
Group 1
Group 2
Total
value
value
HR
95% CI
Total
49 (71%)
20 (29%)
69 (100%)
Recurrent time
0.021
Early relapse
37 (75.5%)
11 (55%)
48 (69.6%)
Late relapse
12 (24.5%)
9 (45%)
21 (30.4%)
Pathology
PTCL-U
28 (57.1%)
13 (65%)
41 (59.4%)
NK/T
18 (36.7%)
5 (25%)
23 (33.3%)
Subcutaneous panniculitis-like
2 (4.1%)
0 (0%)
2 (2.9%)
T-cell lymphoma
ALCL
1 (2.1%)
2 (10%)
3 (4.4%)
Sex
Male
30 (61.2%)
12 (60%)
42 (60.9%)
Female
19 (38.8%)
8 (40%)
27 (39.1%)
Age, years
Median (range)
50 (10–79)
58 (19–80)
59 (10–80)
≤60
20 (40.8%)
9 (45%)
29 (42.0%)
>60
29 (59.2%)
11 (55%)
40 (58.0%)
B-symptoms
0.014
Present
27 (55.1%)
10 (50%)
37 (53.6%)
Absent
22 (44.9%)
10 (50%)
32 (46.4%)
Marrow involvement
0.000
0.042
3.816
1.049–13.886
Present
9 (18.4%)
5 (25%)
14 (20.3%)
Absent
40 (81.6%)
15 (75%)
55 (79.7%)
Splenomegaly
0.010
Present
29 (59.2%)
11 (55%)
40 (58.0%)
Absent
20 (40.8%)
9 (45%)
29 (42.0%)
ECOG performance status
0-1
19 (38.8%)
8 (40%)
27 (39.1%)
2
26 (53.1%)
11 (55%)
37 (53.6%)
≥3
4 (8.1%)
1 (5%)
5 (7.3%)
Stage
0.004
I-II
24 (49.0%)
7 (35%)
31 (44.9%)
III-IV
25 (51.0%)
13 (65%)
38 (55.1%)
IPI
0-1 (low-risk group)
19 (38.8%)
2 (10%)
21 (30.4%)
2-3 (intermediate-risk group)
25 (51.0%)
14 (70%)
39 (56.5%)
4-5 (high-risk group)
5 (10.2%)
4 (20%)
9 (13.1%)
Lymphocyte counts
0.005
0.000
5.305
2.100–13.403
≥1 × 109/L
36 (73.5%)
16 (80%)
52 (75.4%)
<1 × 109/L
13 (26.5%)
4 (20%)
17 (24.6%)
-MG
0.001
>Upper limit of normal
26 (53.1%)
13 (65%)
39 (56.5%)
Normal
23 (46.9%)
7 (35%)
30 (43.5%)
LDH
0.002
0.018
2.538
1.172–5.493
>Upper limit of normal
31 (63.3%)
15 (75%)
46 (66.7%)
Normal
18 (36.7%)
5 (25%)
23 (33.3%)
Previous therapeutic regimen
Radiotherapy
9 (18.4%)
3 (15%)
12 (17.4%)
Chemotherapy
29 (59.2%)
13 (65%)
42 (60.9%)
Chemoradiotherapy
11 (22.4%)
4 (20%)
15 (21.7%)
PTCL-U: peripheral T-cell lymphoma-unspecified, NK/T: extranodal natural killer/T-cell lymphoma, ALCL: anaplastic large cell lymphoma, ECOG: Eastern Cooperative Oncology Group, LDH: lactate dehydrogenase, -MG: serum microglobulin, IPI: International Prognostic Index, HR: hazard ratio, and 95% CI: 95% confidence interval. B-symptoms include unexplained fever over 38°C (100.4°F) for 1-2 weeks, unintentional weight loss of >10% of normal body weight over a period of 6 months or less, and drenching sweats, especially at night. IPI scores were calculated by summing the number of risk factors (age > 60 years, stage III/IV, involved extranodal sites > 1, ECOG performance status > 1, and elevated LDH levels).
